Despite improvements on individual process of care measures for acute myocardial infarction (AMI), little is known about performance on a composite measure of AMI care that assesses the delivery of many components of high-quality AMI care. We sought to examine trends in patient-and hospital-level performance on a composite defect-free care measure, identify disparities in the performance across sociodemographic groups, and identify opportunities to further improve quality and outcomes.
O
ver the past 2 decades, there have been significant improvements in process of care measures among patients with acute myocardial infarction (AMI). 1 In light of these improvements and the absence of meaningful variation across hospitals, several individual process measures have been retired from public reporting. Examples of retired measures include the prescription of aspirin and beta blockers. 2 However, process measures still capture important aspects of the quality of AMI care and merit continued attention to ensure that these gains are sustained once they are phased out of public reporting and payment programs. 1 In addition, differences in the quality of AMI care based on race, sex, and other sociodemographic characteristics may warrant continued monitoring. [3] [4] [5] Composite measures provide a mechanism to evaluate performance on multiple individual process measures of care simultaneously. Advocates for composite measures note that this approach appropriately assesses and promotes the comprehensive delivery of many components of high-quality care rather than narrowly focusing on individual measures and, therefore, align more closely with patient's interests. 6, 7 These measures may play an important role with regards to monitoring overall quality of AMI care, identifying opportunities for improvement, and determining whether patterns of care differ across sociodemographic groups.
The National Cardiovascular Data Registry-Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry-Get With The Guidelines (GWTG) (now known as the Chest Pain -Myocardial Infarction Registry) has developed a composite measure for AMI patients that evaluates the proportion of patients treated at participating hospitals that received defect-free care by meeting all eligible process measures. The measure has been endorsed by the National Quality Forum as suitable for public reporting and may be incorporated into the American College of Cardiology's voluntary public reporting program. However, little is known about trends in performance over time and the extent of hospital variation in performance for this all-or-none composite measure in an era where much of the focus on quality improvement has shifted to outcomes measures. In addition, it is not known whether performance on the composite measure varies based on race, sex, and sociodemographic characteristics. Accordingly, we used data from the National Cardiovascular Data Registry-ACTION Registry-GWTG to characterize recent trends in patientand hospital-level performance on the defect-free care measure and identify opportunities to further improve quality and outcomes for patients with AMI.
METHODS

Data Source and Study Cohort
Details of the ACTION Registry-GWTG including inclusion and exclusion criteria, data collection, and data elements have been described previously. 8 Briefly, participating hospitals collect data on AMI patients using standardized data collection tools including patient demographics; presenting features; prehospital, in-hospital, and hospital discharge therapy; timing of care delivery; laboratory tests; procedure use; and in-hospital patient outcomes. Data submitted to the registry are reviewed for completeness and quality, with sites receiving quarterly data quality feedback reports. In addition, participating hospitals are subject to external auditing to determine the validity of submitted data which have demonstrated high levels of agreement between registry data and clinical chart data. 9 The present study consisted of data of all adult patient discharges with AMI between January 1, 2010, and December 31, 2017, in the ACTION GWTG registry. We restricted the population to patients with information needed to calculate whether the defect-free care measure was met (n=1 014 092 at 954 hospitals). To assess trends in patterns of care, we excluded AMI patients treated at hospitals that did not participate continuously in the registry over the entire study period (n=473 336 at 642 hospitals). Finally, analyses of hospital performance excluded hospitals with fewer than 50 AMI cases in each calendar year to provide more robust estimates of hospital performance (n=17 956 and 90 hospitals).
Definitions and Outcomes
The primary outcome was receipt of defect-free care which includes the after process measures: aspirin administered at arrival, aspirin prescribed at discharge, beta-blocker prescribed
WHAT IS KNOWN
• There has been significant improvement in individual process of care measures among patients with acute myocardial infarction. The National Cardiovascular Data Registry-Acute Coronary Treatment and Intervention Outcomes Network Registry developed a composite measure that evaluates the proportion of acute myocardial infarction patients receiving defect-free care, inclusive of timely reperfusion, guideline-directed medical therapy, and referral to a cardiac rehabilitation program.
• Little is known about the trends in achievement of defect-free care overtime and whether there are disparities in performance based on clinical and sociodemographic characteristics.
WHAT THE STUDY ADDS
• There was improvement in defect-free care from 66% in 2010 to 77% in 2017, with improved performance across clinical and sociodemographic groups. Despite these improvements, nearly 1 in 4 patients did not receive optimal, comprehensive care in 2017.
• Our study highlights the potential utility of the composite measure to guide performance improvement efforts for acute myocardial infarction.
at discharge, statin prescribed at discharge, evaluation of left ventricular systolic function, angiotensin-converting enzyme inhibitor or angiotensin receptor blocker at discharge for patients with systolic dysfunction, smoking cessation counseling, and referral to cardiac rehabilitation at discharge for all patients with AMI. Furthermore, for patients with ST-segment-elevation myocardial infarction, the measure evaluates whether the patient received reperfusion therapy (percutaneous coronary intervention or thrombolytic therapy within 12 hours) in addition to whether the reperfusion therapy was delivered in a timely fashion (time to fibrinolytic therapy <30 minutes, door-to-balloon time <90 minutes). 10 The provision of defect-free care is determined by assessing receipt of each process measure for which the patient is eligible (ie, the ACTION Registry data collection form includes contraindicated for each medication). As such, not all measures apply to all patients. Patients receiving all treatments for which they were eligible for were classified as having received defect-free care.
Statistical Analysis
All analyses were performed at the patient-level, using all AMI records to calculate an estimate, and at the hospital-level, aggregating each hospitals' data to calculate a hospital specific estimate. The proportion of patients receiving defect-free care was calculated within each year of the study to evaluate trends over time. Hospital-level proportions of patients receiving defect-free care across different calendar years were examined using median and interquartile range (IQR) and are displayed using box plots. Patient-level performance was further assessed among prespecified groups of patients based on age, sex, race, insurance status, and type of AMI (non-STsegment-elevation myocardial infarction versus ST-segmentelevation myocardial infarction). Hospital-level performance was assessed among the following prespecified groups: quartiles based on proportion of Medicaid and on proportion of nonwhite patients as well as based upon hospital safety-net status, hospital ownership of for-profit versus nonprofit, and hospital teaching status. The 2011 annual survey from the American Hospital Association was used to determine these hospital characteristics, except the proportion of nonwhite AMI patients in a hospital, which was calculated from the patient-level data. Finally, we examined performance over time after stratifying hospitals into quartiles based on their performance in 2010.
We used the Mann-Kendall trend test at the patientlevel to see if there is any significant difference over the 8 years in patient's characteristics as well as in performance on the defect-free care measure in the overall cohort and the sociodemographic groups of interest. For comparisons between performance in 2010 and 2017, we used χ 2 testing for categorical variables and t test for continuous variables and did not examine for trends. All tests for statistical significance were 2-tailed and evaluated at a significance level of 0.05 corrected for multiple comparisons using the Šidák correction. 11 All statistical analyses were performed using SAS version 9.3 (SAS Institute Inc, Cary, North Carolina). The Human Investigation Committee of the Yale University School of Medicine approved the use of a limited dataset from the ACTION Registry-GWTG for research purposes.
RESULTS
The study cohort included 522 800 patients at 222 hospitals. The characteristics of the patients by year are shown in Table 1 . The number of eligible patients, as well as performance for each process of care measure included as a component of the composite measure, is shown in Table 2 . Performance on prescribing of aspirin, statins, and beta blockers, evaluation of left ventricular systolic function, and referral to smoking cessation was high and sustained over the study period. this represented the most frequent gap among patients who did not receive defect-free care.
Overall, the proportion of patients receiving defectfree care significantly increased from 66.0% (65.6%-66.4%) in 2010 to 77.1% (76.8%-76.5%) in 2017, with plateauing of performance in 2013 (P<0.001) (Table 3). Performance on the composite defect-free care measure in sociodemographic and clinical subgroups are included in Table 3 . Between 2010 and 2017, improvements in performance were observed across all subgroups with the greatest absolute improvement observed for black and Hispanic patients (P<0.001, for all). Despite these improvements, absolute performance among older patients, women, as well as black and Hispanic patients and those with government insurance in 2017 remained significantly lower as compared with performance for younger, male, white, and private insurance patients (P<0.001).
There were significant improvements in hospitallevel performance as well as reduced hospital variation in performance over time (2010, (Figure) . Hospital-level performance across region, safety net status, teaching status, and proportion of patients who are nonwhite and have Medicaid insurance coverage is shown in Table 4 . Improvements were observed in all hospital subgroups (P<0.001 for all), with the largest absolute improvement observed among hospitals serving the highest proportion of minority patients (2010 
DISCUSSION
Our study of trends in performance on an all-or-none, composite measure of quality for patients with AMI reveals significant improvements in the provision of defect-free care, but continued opportunity for improvement with persistent disparities in performance across sociodemographic groups. These findings highlight the potential use of this composite measure for quality improvement, public reporting, and benchmarking.
Composite process of care measures integrate performance on individual measures, assessing the comprehensive delivery of multiple components of high-quality care rather than narrowly focusing on individual domains. The composite AMI measure has been endorsed by the National Quality Forum and is currently included in the quarterly performance reports prepared for hospitals that participate in the ACTION registry. Against this backdrop, our study has 3 major findings with important implications for patients, providers, and policymakers. First, we observed significant improvements in performance on the composite measure over the study period. This finding is consistent with studies of individual AMI processes of care and suggests that improvements have not been limited to measures previously incorporated into public reporting and value based purchasing programs. 12, 13 However the defect-free care composite measure raises the bar for hospitals, requiring that they meet every process measure for which their patients are eligible. From this perspective, nearly 1 in 4 patients with AMI in 2017 had studies focusing on individual process of care measures have reported that longstanding disparities in AMI care have been greatly reduced or even eliminated. 12, 13 These successes notwithstanding, our analysis highlights the reality that performance on the composite measure of AMI care quality continues to lag among vulnerable populations. This further illustrates the utility of a composite measure of AMI quality-enabling the identification of important sociodemographic disparities in care that may be obscured in studies focusing on individual process of care measures. As a corollary, additional focus and interventions are required to improve the quality of AMI care and address residual disparities.
Third, in hospital level analyses we observed significant improvements in performance but substantial variation that persisted in 2017. Evaluating gains in performance between 2010 and 2017, we found that hospitals that performed well on the measure in 2010 were mainly able to maintain their performance, and that the greatest improvements were made at hospitals with the worst performance in 2010. Nonetheless, despite the significant improvements in performance on the composite measure, among the worst performing hospitals in 2017, only 7 in 10 patients received comprehensive, defect-free AMI care.
Our findings should be interpreted in the context of following limitations. First, hospital participation in the National Cardiovascular Data Registry-ACTION Registry-GWTG is voluntary. However, recent analysis demonstrates that performance on process of care measures and clinical outcomes is similar among hospitals that do and do not participate in the registry. 16 Further, if there was a significant selection bias and better performing hospitals were more likely to voluntarily participate, our results would represent a conservative estimate of performance with actual performance gaps and disparities being larger than our results would suggest. Second, we elected to exclude hospitals that did not participate through the entire study period. However, our analysis included 522 800 patients across 222 hospitals, representing one of the most robust examinations of contemporary AMI care. In addition, by restricting to hospitals that continuously participated in the registry we were able to investigate temporal changes in the quality of AMI care. Third, our analysis focused exclusively on process of care measures and therefore does not include other important aspects of care quality such as medication prescription filling, adherence, and completion of cardiac rehabilitation-all of which remain suboptimal. [15] [16] [17] However, prior studies have demonstrated an association between process of care measures for AMI and clinical outcomes. 18 In addition, our focus was on examining the provision of defectfree care for AMI and identifying opportunities for performance improvement. Fourth, we cannot definitively determine whether the observed improvements in the composite measure represent improved care quality or may result from changes in documentation. However, when looking at the absolute number of patients eligible for each component of the composite measure we did not observe significant declines that might suggest systematic efforts to exclude patients from eligibility. In addition, hospitals participating in the National Cardiovascular Data Registry-ACTION Registry-GWTG must meet specified quality standards and randomly identified sites are monitored through annual audits. 9 Fifth, we excluded hospitals delivering care to <50 AMIs/y. Among 90 hospitals that were excluded for this reason, only 2 of them participated in the Registry between 2010 and 2017.
CONCLUSIONS
In conclusion, in this large registry of AMI care in the United States, we observed improvements in the provision of guideline-recommended process of care measures. Nevertheless, nearly 1 in 4 AMI patients do not receive defect-free care. In addition, there are persistent performance gaps among vulnerable populations that merit continued attention.
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